PolyTherics Limited Information

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. PolyTherics' portfolio of services and technologies includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals and through its Cambridge, UK-based subsidiary, Antitope, services for protein immunogenicity assessment and antibody and protein re-engineering technologies are delivered. The group provides its services and technologies to an international client base that includes most of the world's leading biotechnology and pharmaceutical companies. PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individuals' funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.